← Back to Screener
Cerus Corp (CERS)
Price$2.05
Favorite Metrics
Price vs S&P 500 (26W)24.52%
Price vs S&P 500 (4W)4.50%
Market Capitalization$397.80M
All Metrics
P/CF (Annual)82.24x
Book Value / Share (Quarterly)$0.33
P/TBV (Annual)11.14x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)7.48%
Cash Flow / Share (Quarterly)$0.01
Price vs S&P 500 (YTD)-4.42%
Gross Margin (TTM)59.86%
Net Profit Margin (TTM)-6.68%
EPS (TTM)$-0.08
10-Day Avg Trading Volume1.09M
EPS Excl Extra (TTM)$-0.08
Revenue Growth (5Y)15.41%
EPS (Annual)$-0.08
ROI (Annual)-10.55%
Gross Margin (Annual)59.86%
Net Profit Margin (5Y Avg)-18.80%
Cash / Share (Quarterly)$0.43
Revenue Growth QoQ (YoY)13.79%
ROA (Last FY)-7.04%
Revenue Growth TTM (YoY)16.13%
EBITD / Share (TTM)$-0.02
ROE (5Y Avg)-52.08%
Operating Margin (TTM)-3.71%
Cash Flow / Share (Annual)$0.01
P/B Ratio6.19x
P/B Ratio (Quarterly)6.16x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.97x
Net Interest Coverage (TTM)-0.59x
ROA (TTM)-7.29%
EV / EBITDA (TTM)149.91x
EPS Incl Extra (Annual)$-0.08
Current Ratio (Annual)1.73x
Quick Ratio (Quarterly)1.12x
3-Month Avg Trading Volume1.58M
52-Week Price Return57.69%
EV / Free Cash Flow (Annual)416.72x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.62
P/S Ratio (Annual)1.70x
Asset Turnover (Annual)1.05x
52-Week High$2.96
Operating Margin (5Y Avg)-15.13%
EPS Excl Extra (Annual)$-0.08
CapEx CAGR (5Y)18.15%
Tangible BV CAGR (5Y)2.02%
26-Week Price Return31.41%
Quick Ratio (Annual)1.12x
13-Week Price Return-25.18%
Total Debt / Equity (Annual)1.31x
Current Ratio (Quarterly)1.73x
Enterprise Value$461.723
Revenue / Share Growth (5Y)11.98%
Asset Turnover (TTM)1.09x
Book Value / Share Growth (5Y)-11.54%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.99x
Pretax Margin (Annual)-6.54%
Cash / Share (Annual)$0.43
3-Month Return Std Dev64.90%
Gross Margin (5Y Avg)60.54%
Net Income / Employee (TTM)$-0
ROE (Last FY)-24.33%
Net Interest Coverage (Annual)-0.59x
EPS Basic Excl Extra (Annual)$-0.08
P/FCF (TTM)79.77x
Receivables Turnover (TTM)7.77x
EV / Free Cash Flow (TTM)416.72x
Total Debt / Equity (Quarterly)1.31x
EPS Incl Extra (TTM)$-0.08
Receivables Turnover (Annual)7.77x
ROI (TTM)-10.87%
P/S Ratio (TTM)1.70x
Pretax Margin (5Y Avg)-18.64%
Revenue / Share (Annual)$1.23
Tangible BV / Share (Annual)$0.62
Price vs S&P 500 (52W)23.06%
Year-to-Date Return-0.49%
5-Day Price Return1.99%
EPS Normalized (Annual)$-0.08
ROA (5Y Avg)-15.79%
Net Profit Margin (Annual)-6.68%
Month-to-Date Return12.64%
Cash Flow / Share (TTM)$-0.26
EBITD / Share (Annual)$-0.02
Operating Margin (Annual)-3.71%
LT Debt / Equity (Annual)0.63x
P/CF (TTM)82.24x
ROI (5Y Avg)-24.05%
LT Debt / Equity (Quarterly)0.63x
EPS Basic Excl Extra (TTM)$-0.08
P/TBV (Quarterly)11.14x
P/B Ratio (Annual)6.16x
Inventory Turnover (TTM)1.99x
Pretax Margin (TTM)-6.54%
Book Value / Share (Annual)$0.33
Price vs S&P 500 (13W)-27.56%
Beta1.65x
P/FCF (Annual)359.02x
Revenue / Share (TTM)$1.22
ROE (TTM)-26.42%
52-Week Low$1.15
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
CERSCerus Corp | 1.70x | 15.41% | 59.86% | -3.71% | $2.05 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Cerus Corp manufactures pathogen-reduction systems for blood transfusion safety, primarily through its INTERCEPT platelet and plasma products. The company operates globally across the United States, Europe, the Middle East, and select international markets. Blood safety represents its sole business focus and revenue driver.